Protocol Ledger

NCT04250337 · Phase III · COMPLETED

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Interventional Phase III clinical trial protocol NCT04250337 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-03 Enrollment: 228 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04250337
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)228 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04250337
Protocol FieldVerified Registry Value
NCT IdentifierNCT04250337
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment228 participants (ACTUAL)
Registered Start Date2020-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04250337
Hospital Research SiteLocationSite Profile
First OC DermatologyFountain Valley, CAOpen Hospital Dossier ->
Center for Dermatology Clinical Research, Inc.Fremont, CAOpen Hospital Dossier ->
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI